Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Epinephrine Product · 1 trial · 1 indication
pharmacokinetic analysis
pharmacokinetic analysis
pharmacokinetic analysis
pharmacokinetic analysis
| Arm | Type | Description |
|---|---|---|
| Adults with seasonal allergic rhinitis | EXPERIMENTAL | Single administration of 1.6mg or 3.2 mg Epinephrine powder nasal spray, with or without allergenic challenge, and single IM 0.3 mg Epinephrine without allergenic challenge. |
| Name | Type | Description |
|---|---|---|
| Epinephrine Nasal Product, 1.6 mg | DRUG | Single dose Nasal powder spray without allergen challenge |
| Epinephrine nasal product, 1.6 mg + allergen | DRUG | Single dose Nasal powder spray with allergen challenge |
| Epinephrine Injection 0.3 mg | DRUG | Intramuscular injection |
| Epinephrine Nasal Product, 3.2 mg | DRUG | Twice dose Nasal powder spray without allergen challenge |
| Epinephrine Nasal Product, 3.2 mg + allergen | DRUG | Twice dose Nasal powder spray with allergen challenge |
Inclusion Criteria: The following inclusion criteria will be assessed at screening (within 28 days prior to the first drug administration): 1. Non-smoking, male and female subjects from 18 to 55 years of age. 2. Documented Positive skin allergy test during the last year. 3. History of hay fever, s...
Epinephrine Product is an investigational small molecule being developed for the treatment of anaphylaxis, a severe and potentially life-threatening allergic reaction. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Epinephrine Product is being developed by Nasus Pharma Ltd., a biopharmaceutical company. The company's stock is traded under the ticker symbol NSRX.
Epinephrine Product is currently in Phase 1 clinical development. It is an investigational drug and has not yet been approved for commercial use. The drug is being studied for the treatment of anaphylaxis.
Epinephrine Product has one completed Phase 1 clinical trial, identified as NCT04696822, titled 'Bioavailability of Nasal Epinephrine'. This trial enrolled 12 participants in Israel and evaluated the drug in healthy volunteers.
Epinephrine Product is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for the treatment of anaphylaxis. The drug has not yet completed the clinical trials required for regulatory approval.